Antimicrobials: Strategies for targeting obesity and metabolic health?

Gut Microbes

Volumn 4, Issue 1, 2013, Pages

  Murphy, Eileen F ^a   Clarke, Siobhan F ^b,e   Marques, Tatiana M ^b,c   Hill, Colin ^c,e   Stanton, Catherine ^b,c   Paul Ross, R ^b,c   O'Doherty, Robert M ^d   Shanahan, Fergus ^b,e   Cotter, Paul D ^b,c  

^a ALIMENTARY HEALTH LTD   (Ireland)

^b TEAGASC FOOD RESEARCH CENTRE   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Antimicrobials; Firmicutes; Gut microbiota; Metabolic disease; Obesity

Indexed keywords

ACETIC ACID; ADENOSINE PHOSPHATE; ANTIINFECTIVE AGENT; BACTERIOCIN; G PROTEIN COUPLED RECEPTOR; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROPIONIC ACID; RESISTIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BIFIDOBACTERIACEAE; CARDIOVASCULAR DISEASE; DIET; FIRMICUTES; HIGH THROUGHPUT SEQUENCING; HUMAN; INSULIN RESISTANCE; INTESTINE FLORA; LACTOBACILLUS SALIVARIUS; LIPID DIET; LISTERIOSIS; METABOLIC DISORDER; MOUSE MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; WEIGHT CONTROL; ANIMAL; ANTIMICROBIALS; BACTERIUM; CLASSIFICATION; DISEASE MODEL; DRUG EFFECT; GASTROINTESTINAL TRACT; MICROBIOLOGY; MOUSE; REVIEW;

FIRMICUTES;

ANTIMICROBIALS; FIRMICUTES; GUT MICROBIOTA; METABOLIC DISEASE; OBESITY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; DISEASE MODELS, ANIMAL; GASTROINTESTINAL TRACT; MICE; OBESITY;

MLCS; MLOWN;

EID: 84871802965     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Hensrud DD, Klein S. Extreme obesity: a new medical crisis in the United States. Mayo Clin Proc 2006; 81(Suppl):S5-10; PMID:17036573.
2. Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology 2007; 132:2087-102, 3; PMID:17498505; http://dx.doi. org/10.1053/j.gastro.2007.03.052.
3. Clarke S, Murphy E, Nilaweera K, Ross P, Shanahan F, O'Toole PW, et al. The gut microbiota and its relationship to diet and obesity: New insights. Gut Microbes 2012; 3:186-202; PMID:22572830; http://dx.doi.org/10.4161/gmic.20168.
4. Ley RE. Obesity and the human microbiome. Curr Opin Gastroenterol 2010; 26:5-11; PMID:19901833; http://dx.doi.org/10.1097/MOG.0b013e328333d751.
5. Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5:e9085; PMID:20140211; http://dx.doi.org/10.1371/journal. pone.0009085.
6. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102:11070-5; PMID:16033867; http://dx.doi.org/10.1073/pnas.0504978102.
7. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444:1022-3; PMID:17183309; http://dx.doi.org/10.1038/4441022a.
8. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Dietinduced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 2008; 3:213-23; PMID:18407065; http://dx.doi.org/10.1016/j.chom.2008.02.015.
9. Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol 2009; 587:4153-8; PMID:19491241; http://dx.doi. org/10.1113/jphysiol.2009.174136.
10. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444:1027-31; PMID:17183312; http://dx.doi.org/10.1038/nature05414.
11. Murphy EF, Cotter PD, Healy S, Marques TM, O'Sullivan O, Fouhy F, et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 2010; 59:1635-42; PMID:20926643; http://dx.doi. org/10.1136/gut.2010.215665.
12. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen Y-Y, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334:105-8; PMID:21885731; http://dx.doi. org/10.1126/science.1208344.
13. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101:15718-23; PMID:15505215; http://dx.doi.org/10.1073/pnas.0407076101.
14. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007; 104:979-84; PMID:17210919; http://dx.doi.org/10.1073/pnas.0605374104.
15. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56:1761-72; PMID:17456850; http://dx.doi. org/10.2337/db06-1491.
16. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57:1470-81; PMID:18305141; http://dx.doi.org/10.2337/db07-1403.
17. Cani PD, Delzenne NM, Amar J, Burcelin R. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. Pathol Biol (Paris) 2008; 56:305-9; PMID:18178333; http://dx.doi.org/10.1016/j.patbio.2007.09.008.
18. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-dietinduced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50:2374-83; PMID:17823788; http://dx.doi. org/10.1007/s00125-007-0791-0.
19. Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, et al. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008; 22:2416-26; PMID:18326786; http://dx.doi.org/10.1096/fj.07-102723.
20. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 2006; 103:12511-6; PMID:16895997; http://dx.doi.org/10.1073/pnas.0601056103.
21. Martin FP, Dumas ME, Wang Y, Legido-Quigley C, Yap IK, Tang H, et al. A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol Syst Biol 2007; 3:112; PMID:17515922; http://dx.doi.org/10.1038/msb4100153.
22. Wall R, Ross RP, Shanahan F, O'Mahony L, O'Mahony C, Coakley M, et al. Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. Am J Clin Nutr 2009; 89:1393-401; PMID:19357220; http://dx.doi.org/10.3945/ajcn.2008.27023.
23. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101:15718-23; PMID:15505215; http://dx.doi.org/10.1073/pnas.0407076101.
24. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, et al. Effects of the gut microbiota on host adiposity are modulated by the shortchain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci U S A 2008; 105:16767-72; PMID:18931303; http://dx.doi.org/10.1073/pnas.0808567105.
25. Cotter PD, Hill C, Ross RP. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 2005; 3:777-88; PMID:16205711; http://dx.doi. org/10.1038/nrmicro1273.
26. Dunne C, Murphy L, Flynn S, O'Mahony L, O'Halloran S, Feeney M, et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek 1999; 76:279-92; PMID:10532384; http://dx.doi. org/10.1023/A:1002065931997.
27. Rea MC, Dobson A, O'Sullivan O, Crispie F, Fouhy F, Cotter PD, et al. Effect of broad-and narrowspectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A 2011; 108(Suppl 1):4639-44; PMID:20616009; http://dx.doi.org/10.1073/pnas.1001224107.
28. Cotter P. Microbiology: Molecular syringes scratch the surface. Nature 2011; 475:301-3; PMID:21776071; http://dx.doi.org/10.1038/475301a.
29. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al.; MetaHIT Consortium. Enterotypes of the human gut microbiome. Nature 2011; 473:174-80; PMID:21508958; http://dx.doi. org/10.1038/nature09944.
30. Pennisi E. Microbiology. Girth and the gut (bacteria). Science 2011; 332:32-3; PMID:21454769; http://dx.doi.org/10.1126/science.332.6025.32.
31. Murphy EF, Cotter PD, Hogan A, O'Sullivan O, Joyce A, Fouhy F, et al. Divergent metabolic outcomes arising from targeted manipulation of the gut microbiota in diet-induced obesity. Gut 2012; PMID:22345653; http://dx.doi.org/10.1136/gutjnl-2011-300705.
32. Moellering RC Jr. Vancomycin: a 50-year reassessment. Clin Infect Dis 2006; 42(Suppl 1):S3-4; PMID:16323117; http://dx.doi.org/10.1086/491708.
33. Pultz NJ, Stiefel U, Donskey CJ. Effects of daptomycin, linezolid, and vancomycin on establishment of intestinal colonization with vancomycinresistant enterococci and extended-spectrum-betalactamase-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother 2005; 49:3513-6; PMID:16048971; http://dx.doi.org/10.1128/AAC.49.8.3513-3516.2005.
34. Yap IK, Li JV, Saric J, Martin FP, Davies H, Wang Y, et al. Metabonomic and microbiological analysis of the dynamic effect of vancomycin-induced gut microbiota modification in the mouse. J Proteome Res 2008; 7:3718-28; PMID:18698804; http://dx.doi.org/10.1021/pr700864x.
35. Claesson MJ, Li Y, Leahy S, Canchaya C, van Pijkeren JP, Cerdeño-Tárraga AM, et al. Multireplicon genome architecture of Lactobacillus salivarius. Proc Natl Acad Sci U S A 2006; 103:6718-23; PMID:16617113; http://dx.doi.org/10.1073/pnas.0511060103.
36. Flynn S, van Sinderen D, Thornton GM, Holo H, Nes IF, Collins JK. Characterization of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. salivarius UCC118. Microbiology 2002; 148:973-84; PMID:11932444.
37. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CGM. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A 2007; 104:7617-21; PMID:17456596; http://dx.doi. org/10.1073/pnas.0700440104.
38. Riboulet-Bisson E, Sturme MHJ, Jeffery IB, O'Donnell MM, Neville BA, Forde BM, et al. Effect of Lactobacillus salivarius bacteriocin Abp118 on the mouse and pig intestinal microbiota. PLoS One 2012; 7:e31113; PMID:22363561; http://dx.doi. org/10.1371/journal.pone.0031113.
39. Robinson CJ, Young VB. Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes 2010; 1:279-84; PMID:20953272; http://dx.doi.org/10.4161/gmic.1.4.12614.
40. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009; 15:1546-58; PMID:19442172; http://dx.doi.org/10.2174/138161209788168164.
41. Cani PD, Lecourt E, Dewulf EM, Sohet FM, Pachikian BD, Naslain D, et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr 2009; 90:1236-43; PMID:19776140; http://dx.doi.org/10.3945/ajcn.2009.28095.
42. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of lowgrade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012; 3:279-88; PMID:22572877; http://dx.doi.org/10.4161/gmic.19625.
43. Lin HV, Frassetto A, Kowalik EJ Jr., Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One 2012; 7:e35240; PMID:22506074; http://dx.doi.org/10.1371/journal. pone.0035240.
44. Quigley EM. Microf lora modulation of motility. J Neurogastroenterol Motil 2011; 17:140-7; PMID:21602990; http://dx.doi.org/10.5056/jnm.2011.17.2.140.
45. Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, Li K, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012; 488:621-6; PMID:22914093; http://dx.doi. org/10.1038/nature11400.
46. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328:228-31; PMID:20203013; http://dx.doi.org/10.1126/science. 1179721.
47. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 1994; 43:1271-8; PMID:7926300; http://dx.doi.org/10.2337/diabetes.43.11.1271.
48. Serino M, Luche E, Gres S, Baylac A, Bergé M, Cenac C, et al. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut 2011; PMID:22110050.
49. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009; 461:1282-6; PMID:19865172; http://dx.doi.org/10.1038/nature08530.
50. Schwiertz A, Taras D, Schäfer KL, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in Lean and Overweight Healthy Subjects. Obesity 2009.